QNCX (Quince Therapeutics) Shares Outstanding (EOP): 0.69 Mil (As of Mar. 2026)


QNCX Quince Therapeutics Inc QNCX
21 GF Score
Price $17.48
! 2 Warning Signs
View Full Analysis

What is Quince Therapeutics Shares Outstanding (EOP)?

Quince Therapeutics QNCX +1.07% 21 Shares Outstanding (EOP) is 0.69 Mil as of Mar. 2026. GuruFocus rates QNCX with a GF Score™ of 21/100. The stock has 2 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Quince Therapeutics's shares outstanding for the quarter that ended in Mar. 2026 was 0.69 Mil.

Quince Therapeutics's quarterly shares outstanding increased from Dec. 2025 (0.28 Mil) to Mar. 2026 (0.69 Mil). It means Quince Therapeutics issued new shares from Dec. 2025 to Mar. 2026 .

Quince Therapeutics's annual shares outstanding increased from Dec. 2024 (0.22 Mil) to Dec. 2025 (0.28 Mil). It means Quince Therapeutics issued new shares from Dec. 2024 to Dec. 2025 .


Quince Therapeutics  (NAS:QNCX) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Quince Therapeutics Shares Outstanding (EOP) Related Terms


Quince Therapeutics Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Quince Therapeutics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Quince Therapeutics Shares Outstanding (EOP) Chart

Quince Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only 0.15 0.18 0.22 0.22 0.28

Quince Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.27 0.27 0.28 0.69

QNCX vs ATOS, ZIVO, KTTA: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Quince Therapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quince Therapeutics Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quince Therapeutics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Quince Therapeutics's Shares Outstanding (EOP) falls into.


QNCX
21GF Score
Quince Therapeutics Inc QNCX
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Quince Therapeutics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 0.69 Mil mean?
Quince Therapeutics (QNCX) has a Shares Outstanding (EOP) of 0.69 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Quince Therapeutics and its competitors.
Is Quince Therapeutics' Shares Outstanding (EOP) too high?
Quince Therapeutics' current Shares Outstanding (EOP) is 0.69 Mil. Overall, Quince Therapeutics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Quince Therapeutics' Shares Outstanding (EOP) compare to ATOS and ZIVO?
Quince Therapeutics' Shares Outstanding (EOP) of 0.69 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Quince Therapeutics and its competitors. Quince Therapeutics's current Shares Outstanding (EOP) is 0.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quince Therapeutics stock overvalued right now?
Quince Therapeutics (QNCX) has a current Shares Outstanding (EOP) of 0.69 Mil. The current Shares Outstanding (EOP) is 0.69 Mil. Quince Therapeutics' overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Quince Therapeutics (QNCX), the current Shares Outstanding (EOP) is 0.69 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Quince Therapeutics Business Description

Address 611 Gateway Boulevard, Suite 273, South San Francisco, CA, USA, 94080
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
21GF Score

Get the complete analysis for QNCX

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.48
Price